01—Abstract
Summary
Summary of the 10-Q filed April 24, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. reported first-quarter 2025 net sales of $698.0 milliona, up from $695.4 million in the prior-year quarter, a 0.4% increase as reported and 2.1% excluding foreign currency translation.
Proprietary Products net sales rose 0.6%b as reported (2.4% organic), led by self-injection device platforms, partly offset by lower FluroTec products sales. Contract-Manufactured Products net sales fell 0.7% as reported, though they rose 0.8% organically on self-injection devices for obesity and diabetes. Gross margin was 33.2% versus 33.1% a year earlier.
Profitability declined. GAAP operating profit fell 12.9% to $107.0 million, and net income dropped to $89.8 millionc from $115.3 million. Diluted EPS was $1.23 versus $1.55.
The decline was driven mainly by $16.4 milliond of restructuring and related charges in other expense (income), tied to a 2025 restructuring plan approved in January 2025 with expected total charges of roughly $30 million to $32 million and annualized savings of $35 million to $40 million. Excluding unallocated items, adjusted operating profit was $125.0 million (17.9% margin) and adjusted diluted EPS was $1.45 versus $1.56. The effective tax rate rose to 21.8% from 12.9%, mainly due to a smaller stock-compensation tax benefit.
Cash generation and capital return were the key liquidity themes. Operating cash flow was $129.4 million, capital expenditures were $71.3 million, and the company repurchased 550,281 shares for $133.5 million.
Cash and cash equivalents declined to $404.2 million from $484.6 million at year-end, while debt held steady at $202.6 million and $497.7 million remained available under the revolving credit facility. Management stated that tariffs are not expected to be material to 2025 results, and the company was in compliance with all debt covenants.
02—Key points
Key Highlights
- Net sales of $698.0 million, up 0.4% as reported and 2.1% excluding currency translation, versus $695.4 million a year earlier.
- GAAP operating profit fell 12.9% to $107.0 million; net income was $89.8 million versus $115.3 million, and diluted EPS was $1.23 versus $1.55.
- Adjusted operating profit of $125.0 million (17.9% margin) and adjusted diluted EPS of $1.45, excluding $17.8 million of restructuring and other unallocated charges and related items.
- A January 2025 restructuring plan carries expected charges of approximately $30 million to $32 million and annualized savings of $35 million to $40 million; $16.4 million was recorded in other expense in Q1.
- Proprietary Products sales grew 2.4% organically on self-injection device platforms, while Contract-Manufactured Products grew 0.8% organically on self-injection devices for obesity and diabetes.
- Operating cash flow of $129.4 million funded $71.3 million of capital expenditures and $133.5 million of share repurchases; cash fell to $404.2 million.
- Debt remained at $202.6 million, with $497.7 million of revolving credit capacity available and covenant compliance at March 31, 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, West Pharmaceutical Services kept $0.13.
- Revenue$698.0M100.0%
- Cost of revenue−$466.1M66.8%
- Gross profit$231.9M33.2%
- Operating costs−$124.9M17.9%
- Operating income$107.0M15.3%
- Interest, other & tax−$17.2M2.5%
- Net income$89.8M12.9%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 24, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $698.00M$695.40M | +0.4% |
| Cost of Revenue | $466.10M$465.20M | +0.2% |
| Gross Profit | $231.90M$230.20M | +0.7% |
| R&D Expenses | $16.30M$17.60M | −7.4% |
| SG&A Expenses | $88.00M$86.70M | +1.5% |
| Operating Income | $107.00M$122.80M | −12.9% |
| Net Income | $89.80M$115.30M | −22.1% |
| EPS (Basic) | $1.24$1.57 | −21.0% |
| EPS (Diluted) | $1.23$1.55 | −20.6% |
| Shares Outstanding (Basic) | 72.50M73.50M | −1.4% |
| Shares Outstanding (Diluted) | 73.00M74.30M | −1.7% |
05—Questions
Frequently Asked Questions
Why did earnings decline despite higher net sales?
Operating profit fell 12.9% to $107.0 million, mainly because of $16.4 million of restructuring and related charges recorded in other expense (income) under the 2025 restructuring plan. Other expense rose to $20.6 million from $3.1 million, and the effective tax rate increased to 21.8% from 12.9%, largely due to a smaller tax benefit from stock-based compensation. Excluding unallocated items, adjusted operating profit was $125.0 million versus $123.0 million in the prior-year quarter.
What is the restructuring plan and what savings does it target?
In January 2025, the company approved a plan to adjust its operating cost base in response to macroeconomic factors. It is expected to be implemented over approximately twenty-four to thirty-six months and to require restructuring and related charges of approximately $30 million to $32 million, with annualized savings of $35 million to $40 million. As of March 31, 2025, the remaining restructuring obligation was $11.1 million, mostly severance and benefits.
How is the company returning capital to shareholders?
During the quarter, West repurchased 550,281 shares for $133.5 million at an average price of $242.63 per share, and paid $15.2 million in dividends ($0.21 per share). The $1.0 billion program approved in February 2023 was completed in January 2025, and the 550,000-share program approved in December 2024 was completed in April 2025. Share repurchases were $267.0 million in the prior-year quarter.
How strong is the balance sheet and liquidity position?
Cash and cash equivalents were $404.2 million at March 31, 2025, down from $484.6 million at December 31, 2024. Total debt was $202.6 million, with $130.0 million under a term loan and $73.0 million of Series C notes. The $500.0 million multi-currency revolving credit facility had $497.7 million of borrowing capacity available, and management believes cash on hand, operating cash flow and the facility will cover foreseeable needs.
What does the filing say about tariffs and the Israel-based operations?
Management stated that, based on current information, the impact of newly imposed U.S. tariffs and retaliatory measures by other jurisdictions is not expected to be material to 2025 results, and it continues to monitor the situation. The company also has Israel-based facilities that conduct research and development and manufacture certain components. Those facilities continue to substantially operate as they did before the conflict in Israel and surrounding areas, and management is monitoring potential effects on operations and suppliers.
06—Continue